A number of studies have been performed that compare the recently developed PET tracer for prostate cancer, Fluorine-18 labeled DCFPyL, with Gallium-68 tracers that have been in use for a number of years.
A recent paper by Felix Dietlein et al Dec 1 2016, published in The Journal of Nuclear Medicine, is titled “PSA-stratified performance of the 18F-labeled PSMA tracer 18F-DCFPyL and the 68Ga-labeled reference 68Ga-PSMA-HBED-CC”. (place mouse over title and clink for Article)
In this study they examined 191 consecutive patients with biochemical recurrence according to standard acquisition protocols with 18F-DCFPyL (N = 62, 269.8 MBq, PET scan at 120 minutes p.i.) or 68Ga-PSMA-HBED-CC (N = 129, 158.9 MBq, 60 minutes p.i.)
The paper draws the following conclusion:
“Our data suggest that 18F-DCFPyL is non-inferior to 68Ga-PSMA-HBED-CC, while offering the advantages of 18F-labeling. Our results indicate that imaging with 18F-DCFPyL may even exhibit improved sensitivity in localizing relapsed tumors after prostatectomy for moderately increased PSA levels. Although the standard acquisition protocols, used for 18F-DCFPyL and 68Ga-PSMA-HBED-CC in this study, stipulate different activity doses and tracer uptake times after injection, our findings provide a promising rationale for validation of 18F-DCFPyL in future prospective trials”
Cyclotek has completed the manufacturing validation of DCFPyL and is working on clinical studies designed for marketing authorization and potential MBS rebate.
Cyclotek’s proposed product name for 18F-DCFPyL is PSR, Prostate Specific Radiopharmaceutical.
Please contact Dr Rob Ware (Cyclotek Clinical Director) or David Krenus (Regulatory Affairs Director) for any further information at enquiries@cyclotek.com.
[contact-form-7 id=”714″ title=”Update Form”]
